Tumors as elusive targets of T-cell-based active immunotherapy.

Francesco M. Marincola, Ena Wang, Meenhard Herlyn, Barbara Seliger, Soldano Ferrone

Research output: Contribution to journalReview article

Abstract

The understanding of tumor-host interactions remains elusive despite significant progress in the identification of tumor antigens (TAs) recognized by autologous T cells. In particular, most human tumors do not regress and continue to grow in spite of spontaneous or immunization-induced immune responses demonstrated in circulating lymphocytes. Indeed, systemic immune responses might insufficiently address the complexity of tumor-host interactions because of factors, such as (1) the lack of productive T-cell receptor (TCR) engagement with epitope owing to qualitative and/or quantitative defects in the generation and maintenance of the immune response, (2) insufficient costimulation provided by the host, (3) the lack of localization of the immune response in target tissues and (4) the complexity of tumor-host interactions within the tumor microenvironment caused by temporal changes in tumor phenotypes and an array of immune mediators expressed in the tumor microenvironment. Here, we will review current knowledge of the different 'levels' of immune response that might be necessary for immunotherapy to be effective in the treatment of cancer. Furthermore, we will discuss the information still required in order to understand the mechanism(s) governing tumor rejection by the immune system in response to TA-specific immunization.

Original languageEnglish
Pages (from-to)335-342
Number of pages8
JournalTrends in Immunology
Volume24
Issue number6
Publication statusPublished - Jun 2003
Externally publishedYes

Fingerprint

Active Immunotherapy
T-Lymphocytes
Neoplasms
Tumor Microenvironment
Neoplasm Antigens
Immunization
T-Cell Antigen Receptor
Immunotherapy
Epitopes
Immune System
Maintenance
Lymphocytes
Phenotype

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Marincola, F. M., Wang, E., Herlyn, M., Seliger, B., & Ferrone, S. (2003). Tumors as elusive targets of T-cell-based active immunotherapy. Trends in Immunology, 24(6), 335-342.

Tumors as elusive targets of T-cell-based active immunotherapy. / Marincola, Francesco M.; Wang, Ena; Herlyn, Meenhard; Seliger, Barbara; Ferrone, Soldano.

In: Trends in Immunology, Vol. 24, No. 6, 06.2003, p. 335-342.

Research output: Contribution to journalReview article

Marincola, FM, Wang, E, Herlyn, M, Seliger, B & Ferrone, S 2003, 'Tumors as elusive targets of T-cell-based active immunotherapy.', Trends in Immunology, vol. 24, no. 6, pp. 335-342.
Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends in Immunology. 2003 Jun;24(6):335-342.
Marincola, Francesco M. ; Wang, Ena ; Herlyn, Meenhard ; Seliger, Barbara ; Ferrone, Soldano. / Tumors as elusive targets of T-cell-based active immunotherapy. In: Trends in Immunology. 2003 ; Vol. 24, No. 6. pp. 335-342.
@article{88a8b8fcc1394c35ad3109c9678c4148,
title = "Tumors as elusive targets of T-cell-based active immunotherapy.",
abstract = "The understanding of tumor-host interactions remains elusive despite significant progress in the identification of tumor antigens (TAs) recognized by autologous T cells. In particular, most human tumors do not regress and continue to grow in spite of spontaneous or immunization-induced immune responses demonstrated in circulating lymphocytes. Indeed, systemic immune responses might insufficiently address the complexity of tumor-host interactions because of factors, such as (1) the lack of productive T-cell receptor (TCR) engagement with epitope owing to qualitative and/or quantitative defects in the generation and maintenance of the immune response, (2) insufficient costimulation provided by the host, (3) the lack of localization of the immune response in target tissues and (4) the complexity of tumor-host interactions within the tumor microenvironment caused by temporal changes in tumor phenotypes and an array of immune mediators expressed in the tumor microenvironment. Here, we will review current knowledge of the different 'levels' of immune response that might be necessary for immunotherapy to be effective in the treatment of cancer. Furthermore, we will discuss the information still required in order to understand the mechanism(s) governing tumor rejection by the immune system in response to TA-specific immunization.",
author = "Marincola, {Francesco M.} and Ena Wang and Meenhard Herlyn and Barbara Seliger and Soldano Ferrone",
year = "2003",
month = "6",
language = "English",
volume = "24",
pages = "335--342",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Tumors as elusive targets of T-cell-based active immunotherapy.

AU - Marincola, Francesco M.

AU - Wang, Ena

AU - Herlyn, Meenhard

AU - Seliger, Barbara

AU - Ferrone, Soldano

PY - 2003/6

Y1 - 2003/6

N2 - The understanding of tumor-host interactions remains elusive despite significant progress in the identification of tumor antigens (TAs) recognized by autologous T cells. In particular, most human tumors do not regress and continue to grow in spite of spontaneous or immunization-induced immune responses demonstrated in circulating lymphocytes. Indeed, systemic immune responses might insufficiently address the complexity of tumor-host interactions because of factors, such as (1) the lack of productive T-cell receptor (TCR) engagement with epitope owing to qualitative and/or quantitative defects in the generation and maintenance of the immune response, (2) insufficient costimulation provided by the host, (3) the lack of localization of the immune response in target tissues and (4) the complexity of tumor-host interactions within the tumor microenvironment caused by temporal changes in tumor phenotypes and an array of immune mediators expressed in the tumor microenvironment. Here, we will review current knowledge of the different 'levels' of immune response that might be necessary for immunotherapy to be effective in the treatment of cancer. Furthermore, we will discuss the information still required in order to understand the mechanism(s) governing tumor rejection by the immune system in response to TA-specific immunization.

AB - The understanding of tumor-host interactions remains elusive despite significant progress in the identification of tumor antigens (TAs) recognized by autologous T cells. In particular, most human tumors do not regress and continue to grow in spite of spontaneous or immunization-induced immune responses demonstrated in circulating lymphocytes. Indeed, systemic immune responses might insufficiently address the complexity of tumor-host interactions because of factors, such as (1) the lack of productive T-cell receptor (TCR) engagement with epitope owing to qualitative and/or quantitative defects in the generation and maintenance of the immune response, (2) insufficient costimulation provided by the host, (3) the lack of localization of the immune response in target tissues and (4) the complexity of tumor-host interactions within the tumor microenvironment caused by temporal changes in tumor phenotypes and an array of immune mediators expressed in the tumor microenvironment. Here, we will review current knowledge of the different 'levels' of immune response that might be necessary for immunotherapy to be effective in the treatment of cancer. Furthermore, we will discuss the information still required in order to understand the mechanism(s) governing tumor rejection by the immune system in response to TA-specific immunization.

UR - http://www.scopus.com/inward/record.url?scp=0042967953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042967953&partnerID=8YFLogxK

M3 - Review article

VL - 24

SP - 335

EP - 342

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 6

ER -